市場調查報告書

溶小體儲積症治療的全球市場:市場規模、佔有率、預測、機會分析 - 各治療方法、適應症、終端用戶、地區

Lysosomal Storage Diseases Therapeutics Market: By Treatment, By Indication, By End User, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

出版商 Coherent Market Insights 商品編碼 931886
出版日期 內容資訊 英文 171 Pages
商品交期: 2-3個工作天內
價格
溶小體儲積症治療的全球市場:市場規模、佔有率、預測、機會分析 - 各治療方法、適應症、終端用戶、地區 Lysosomal Storage Diseases Therapeutics Market: By Treatment, By Indication, By End User, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
出版日期: 2020年03月17日內容資訊: 英文 171 Pages
簡介

稱作溶小體儲積症的引起特定病情的酵素缺乏症中,有法布瑞氏症,高雪氏症,溶酶體酸性脂肪酶缺乏症,黏多醣症,韓特氏症,龐貝氏症等。酵素補充療法,為了補充不足的酵素和失去的酵素進行酵素的靜脈注射,已知比其他治療方法副作用少。

本報告提供全球溶小體儲積症治療市場調查,市場概要,各治療方法、適應症、終端用戶、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 與調查目的假設

  • 調查目的
  • 假設
  • 簡稱

第2章 市場展望

  • 報告概要
    • 市場定義和範圍
  • 摘要整理
    • 市場片段:各治療法
    • 市場片段:各適應症
    • 市場片段:各地區
  • Coherent Opportunity Map(COM)

第3章 市場動態、規定、趨勢分析

  • 市場動態
  • 成長要素
  • 阻礙因素
  • 市場機會
  • 影響分析
  • 主要趨勢
  • 法規方案
  • PEST分析
  • 開發平台分析

第4章 全球溶小體儲積症治療市場:各治療法

  • 簡介
    • 市場佔有率分析(成果值、預測值)
    • 與前一年同期比較成長率分析
    • 市場趨勢:各治療法
  • 酵素補充療法(ERT)
  • 幹細胞療法
  • 基材合成抑制療法(SRT)
  • 其他

第5章 全球溶小體儲積症治療市場:各適應症

  • 簡介
    • 市場佔有率分析(成果值、預測值)
    • 與前一年同期比較成長率分析
    • 市場趨勢:各適應症
  • 高雪氏症
  • 法布瑞氏症
  • 龐貝氏症
  • 黏多醣症
  • 其他

第6章 全球溶小體儲積症治療市場:各終端用戶

  • 簡介
    • 市場佔有率分析(成果值、預測值)
    • 與前一年同期比較成長率分析
    • 市場趨勢:各終端用戶
  • 醫院
  • 診療所

第7章 全球溶小體儲積症治療市場:各地區

  • 簡介
    • 市場佔有率分析(成果值、預測值)
    • 與前一年同期比較成長率分析
    • 市場趨勢:各地區
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東
  • 非洲

第8章 競爭情形

  • 企業簡介
    • Shire plc
    • Pfizer, Inc.
    • Sanofi SA
    • BioMarin Pharmaceutical Inc
    • Actelion Ltd.
    • Raptor Pharmaceutical Corp.
    • Protalix Biotherapeutics Inc.
    • Amicus Therapeutics, Inc.

第9章 Section

  • 參考資料
  • 調查手法
  • 關於Coherant Market Insights
目錄

The deficiency of enzymes that causes a specific disease condition called lysosomal storage disease includes diseases such as Fabry Disease, Gaucher disease, lysosomal acid lipase deficiency, mucopolysaccharidosis, Hunter syndrome, and Pompe disease. Enzyme replacement therapy involves intravenous administration of enzymes in order to correct the deficiency of enzymes. Enzyme replacement is associated with fewer side effects than other treatment methods. Enzymes are obtained from sources such as human cells, animal cells, and recombinant DNA technology. Enzyme replacement, although does not provide permanent cure, helps prevents permanent damage to the body caused due to deficiency of a specific enzyme. Treatment consists of weekly or monthly doses depending upon the disease.

Restraints of the Global Lysosomal Storage Diseases Therapeutics Market

Factors such as high cost associated with the enzyme replacement therapy and complex reimbursement scenario causing therapy to be excluded from coverage by insurers due to this being rare diseases, hamper growth of the market over the forecast period.

Key features of the study:

This report provides in-depth analysis of the global lysosomal storage diseases therapeutics market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019-2027), considering 2018, as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players

It profiles leading players in the global lysosomal storage diseases therapeutics market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans

Key companies covered as a part of this study include Shire plc, Pfizer, Inc., Sanofi, BioMarin Pharmaceutical Inc., Actelion Ltd., Raptor Pharmaceutical Corp., Protalix Biotherapeutics Inc., Quest Diagnostics, and Amicus Therapeutics, Inc.

Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics

The global lysosomal storage diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

Global Lysosomal Storage Diseases Therapeutics Market, By Treatment:

Enzyme Replacement Therapy

Stem Cell Therapy

Substrate Reduction Therapy

Others

Global Lysosomal Storage Diseases Therapeutics Market, By Indication:

Gaucher's Disease

Fabry Disease

Pompe's Syndrome

Mucopolysaccharidosis

Others

Global Lysosomal Storage Diseases Therapeutics Market, By End User:

Hospitals

Clinics

Global Lysosomal Storage Diseases Therapeutics Market, By Geography:

North America

By Treatment

Enzyme Replacement Therapy

Stem Cell Therapy

Substrate Reduction Therapy

Others

By Indication

Gaucher's Diseases

Fabry Diseases

Pompe's Syndrome

Mucopolysaccharidosis

Other

By End User

Hospitals

Clinics

By Country:

U.S.

Canada

Europe

By Treatment

Enzyme Replacement Therapy

Stem Cell Therapy

Substrate Reduction Therapy

Others

By Indication

Gaucher's Diseases

Fabry Diseases

Pompe's Syndrome

Mucopolysaccharidosis

Other

By End User

Hospitals

Clinics

By Country:

U.K.

Germany

Italy

France

Spain

Russia

Rest of Europe

Asia Pacific

By Treatment

Enzyme Replacement Therapy

Stem Cell Therapy

Substrate Reduction Therapy

Others

By Indication

Gaucher's Diseases

Fabry Diseases

Pompe's Syndrome

Mucopolysaccharidosis

Other

By End User

Hospitals

Clinics

By Country:

China

India

Japan

ASEAN

Australia

South Korea

Rest of Asia Pacific

Latin America

By Treatment

Enzyme Replacement Therapy

Stem Cell Therapy

Substrate Reduction Therapy

Others

By Indication

Gaucher's Diseases

Fabry Diseases

Pompe's Syndrome

Mucopolysaccharidosis

Other

By End User

Hospitals

Clinics

By Country:

Brazil

Mexico

Argentina

Rest of Latin America

Middle East:

By Treatment

Enzyme Replacement Therapy

Stem Cell Therapy

Substrate Reduction Therapy

Others

By Indication

Gaucher's Diseases

Fabry Diseases

Pompe's Syndrome

Mucopolysaccharidosis

Other

By End User

Hospitals

Clinics

By Country:

GCC

Israel

Rest of Middle East

Africa

By Treatment

Enzyme Replacement Therapy

Stem Cell Therapy

Substrate Reduction Therapy

Others

By Indication

Gaucher's Diseases

Fabry Diseases

Pompe's Syndrome

Mucopolysaccharidosis

Other

By End User

Hospitals

Clinics

By Country/Region:

Central Africa

South Africa

North Africa

Company Profiles

Shire plc*

Company Overview

Product Portfolio

Financial Performance

Key Strategies

Recent Developments

Pfizer, Inc.

Sanofi SA

BioMarin Pharmaceutical Inc

Actelion Ltd.

Raptor Pharmaceutical Corp.

Protalix Biotherapeutics Inc.

Amicus Therapeutics, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
  • Market Definition and Scope
    • Executive Summary
  • Market Snippet, By Treatment
  • Market Snippet, By Indication
  • Market Snippet, By End User
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • Pipeline Analysis

4. Global Lysosomal Storage Diseases Therapeutics Market, By Treatment, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Enzyme Replacement Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Stem Cell Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Substrate Reduction Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends

5. Global Lysosomal Storage Diseases Therapeutics Market, By Indication, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Gaucher's Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Fabry Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Pompe's Syndrome
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Mucopolysaccharidosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

6. Global Lysosomal Storage Diseases Therapeutics Market, By End User, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

7. Global Lysosomal Storage Diseases Therapeutics Market, By Regions, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
    • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

    • Company Profiles
  • Shire plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi SA
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • BioMarin Pharmaceutical Inc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Actelion Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Raptor Pharmaceutical Corp.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Protalix Biotherapeutics Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Amicus Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Section

    • References
    • Research Methodology
    • About us and Sales Contact